Real world study on antiviral efficacy and safety in patients with normal ALT chronic hepatitis B
10.3969/j.issn.1671-8348.2025.01.025
- VernacularTitle:ALT正常的慢性乙型肝炎患者抗病毒治疗疗效和安全性的真实世界研究
- Author:
Jing WANG
1
;
Jiaqi WANG
;
Fang CHEN
;
Jie XIA
;
Lufeng LI
;
Qing MAO
Author Information
1. 中国人民解放军陆军军医大学第一附属医院全军感染病研究所/感染病研究重庆市重点实验室,重庆 400038
- Keywords:
chronic hepatitis B;
liver cirrhosis;
liver cancer;
alanine aminotransferase;
hepatitis B virus;
complete virological response rate
- From:
Chongqing Medicine
2025;54(1):138-141
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of antiviral therapy in the patients with normal ALT chronic hepatitis B(CHB).Methods The clinical data of the patients with normal ALT CHB visiting in this hospital from December 2019 to December 2023 were collected.The patients were divided into the low vi-ral load group(HBV DNA＜2×106 IU/mL,n=76)and high viral load group(HBV DNA≥2×106 IU/mL,n=10).ETV,TDF and TAF were adopted to conduct the single drug antivirus therapy.The basic informa-tion,demographic characteristics,HBV DNA levels in initial treatment and after 12,24,36,48 weeks of treat-ment,estimated glomerular filtration rate(eGFR)were collected.The rate of complete virological response(CVR)at each time point conducted the statistics for evaluating the effect.The drug safety was evaluated by the eGFR level in 48 weeks of treatment.Results The CVR rates in 12,24,36 weeks of treatment in the low viral load group were 81.6％,94.7％,100.0％and 100.0％respectively,which in the high viral load group were 40.0％,80.0％,80.0％and 80.0％respectively.There was no significant change in eGFR level(109.41±170.57)mL·min-1·1.73 m-2 at 48 weeks of treatment compared with baseline(108.47±110.83)mL·min-1·1.73 m-2(P＞0.05).The ALT and creatinine levels during the treatment process in all the patients were not increased.There was no case of drug withdrawal and drug change due to the drug side effects.Conclusion The overall efficacy and safety of ETV,TDF and TAF monotherapy are good in CHB pa-tients with a family history of cirrhosis or liver cancer and normal ALT.The patients with high viral load at baseline are less likely to achieve CVR in 48 weeks of treatment.
